Skip to main content
Top
Published in: AIDS and Behavior 9/2021

Open Access 01-09-2021 | Human Immunodeficiency Virus | Original Paper

Understanding the Reasons for Deferring ART Among Patients Diagnosed Under the Same-Day-ART Policy in Johannesburg, South Africa

Authors: Dorina Onoya, Tembeka Sineke, Idah Mokhele, Jacob Bor, Matthew P. Fox, Jacqui Miot

Published in: AIDS and Behavior | Issue 9/2021

Login to get access

Abstract

We aimed to examine the correlates of antiretroviral therapy (ART) deferral to inform ART demand creation and retention interventions for patients diagnosed with HIV during the Universal Test and Treat (UTT) policy in South Africa. We conducted a cohort study enrolling newly diagnosed HIV-positive adults (≥ 18 years), at four primary healthcare clinics in Johannesburg between October 2017 and August 2018. Patients were interviewed immediately after HIV diagnosis, and ART initiation was determined through medical record review up to six-months post-test. ART deferral was defined as not starting ART six months after HIV diagnosis. Participants who were not on ART six-months post-test were traced and interviewed telephonically to determine reasons for ART deferral. Modified Poisson regression was used to evaluate correlates of six-months ART deferral. We adjusted for baseline demographic and clinical factors. We present crude and adjusted risk ratios (aRR) associated with ART deferral. Overall, 99/652 (15.2%) had deferred ART by six months, 20.5% men and 12.2% women. Baseline predictors of ART deferral were older age at diagnosis (adjusted risk ratio (aRR) 1.5 for 30–39.9 vs 18–29.9 years, 95% confidence intervals (CI): 1.0–2.2), disclosure of intentions to test for HIV (aRR 2.2 non-disclosure vs disclosure to a partner/spouse, 95% CI: 1.4–3.6) and HIV testing history (aRR 1.7 for  > 12 months vs < 12 months/no prior test, 95% CI: 1.0–2.8). Additionally, having a primary house in another country (aRR 2.1 vs current house, 95% CI: 1.4–3.1) and testing alone (RR 4.6 vs partner/spouse support, 95% CI: 1.2–18.3) predicted ART deferral among men. Among the 43/99 six-months interviews, women (71.4%) were more likely to self-report ART initiation than men (RR 0.4, 95% CI: 0.2–0.8) and participants who relocated within SA (RR 2.1 vs not relocated, 95% CI: 1.2–3.5) were more likely to still not be on ART. Under the treat-all ART policy, nearly 15.2% of study participants deferred ART initiation up to six months after the HIV diagnosis. Our analysis highlighted the need to pay particular attention to patients who show little social preparation for HIV testing and mobile populations.
Literature
1.
go back to reference UNAIDS. Global AIDS update 2016. Geneva, Switzerland: World Health Organization Library; 2016. UNAIDS. Global AIDS update 2016. Geneva, Switzerland: World Health Organization Library; 2016.
2.
go back to reference HSRC. The fifth south african national HIV prevalence incidence behaviour and communication survey 2017. Pretoria: HSRC; 2018. HSRC. The fifth south african national HIV prevalence incidence behaviour and communication survey 2017. Pretoria: HSRC; 2018.
3.
go back to reference South African National Department of Health (SA-NDoH). National department of health annual report 2018/2019. Pretoria: SA-NDoH; 2019. South African National Department of Health (SA-NDoH). National department of health annual report 2018/2019. Pretoria: SA-NDoH; 2019.
6.
go back to reference Rosen S, Fox MP, Larson BA, et al. Accelerating the uptake and timing of antiretroviral therapy initiation in sub-saharan Africa: an operations research agenda. PLoS Med. 2016;13(8):e1002106.CrossRef Rosen S, Fox MP, Larson BA, et al. Accelerating the uptake and timing of antiretroviral therapy initiation in sub-saharan Africa: an operations research agenda. PLoS Med. 2016;13(8):e1002106.CrossRef
7.
go back to reference Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRef Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.CrossRef
8.
go back to reference Boyer S, Iwuji C, Gosset A, et al. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care. 2016;28(sup3):39–51.CrossRef Boyer S, Iwuji C, Gosset A, et al. Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care. 2016;28(sup3):39–51.CrossRef
9.
go back to reference SA-NDoH. National policy on HIV pre-exposure prophylaxis (PrEP) and test and treat (T&T). Pretoria: SA-NDoH; 2016. SA-NDoH. National policy on HIV pre-exposure prophylaxis (PrEP) and test and treat (T&T). Pretoria: SA-NDoH; 2016.
12.
go back to reference SA-NDoH. Fast tracking implementation of the 90–90-90 strategy for HIV through implementation of the test and treat (TT) policy and same-day antiretroviral therapy (ART) initiation for positive patients. Pretoria: SA-NDoH; 2017. SA-NDoH. Fast tracking implementation of the 90–90-90 strategy for HIV through implementation of the test and treat (TT) policy and same-day antiretroviral therapy (ART) initiation for positive patients. Pretoria: SA-NDoH; 2017.
13.
go back to reference WHO. Consolidated guidelines for the use antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016. WHO. Consolidated guidelines for the use antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: WHO; 2016.
14.
go back to reference Nachega JB, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the achilles’ heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59(suppl 1):S21–7.CrossRef Nachega JB, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the achilles’ heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis. 2014;59(suppl 1):S21–7.CrossRef
15.
go back to reference Labhardt ND, Ringera I, Lejone TI, et al. Same day ART initiation versus clinic-based pre-ART assessment and counselling for individuals newly tested HIV-positive during community-based HIV testing in rural lesotho–a randomized controlled trial (CASCADE trial). BMC Public Health. 2016;16(1):329.CrossRef Labhardt ND, Ringera I, Lejone TI, et al. Same day ART initiation versus clinic-based pre-ART assessment and counselling for individuals newly tested HIV-positive during community-based HIV testing in rural lesotho–a randomized controlled trial (CASCADE trial). BMC Public Health. 2016;16(1):329.CrossRef
17.
go back to reference Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, et al. Factors associated with late antiretroviral therapy initiation among adults in mozambique. PLoS ONE. 2012;7(5):e37125.CrossRef Lahuerta M, Lima J, Nuwagaba-Biribonwoha H, et al. Factors associated with late antiretroviral therapy initiation among adults in mozambique. PLoS ONE. 2012;7(5):e37125.CrossRef
18.
go back to reference Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7(4):234–44.CrossRef Geng EH, Nash D, Kambugu A, et al. Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep. 2010;7(4):234–44.CrossRef
19.
go back to reference Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280–9.CrossRef Kigozi IM, Dobkin LM, Martin JN, et al. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in sub-saharan Africa. J Acquir Immune Defic Syndr. 2009;52(2):280–9.CrossRef
20.
go back to reference Fox MP. Are we shifting attrition downstream in the HIV cascade? Lancet HIV. 2016;3(12):e554–5.CrossRef Fox MP. Are we shifting attrition downstream in the HIV cascade? Lancet HIV. 2016;3(12):e554–5.CrossRef
21.
go back to reference Katz IT, Essien T, Marinda ET, et al. Antiretroviral refusal among newly diagnosed HIV-infected adults in soweto, South Africa. AIDS. 2011;25(17):2177–81.CrossRef Katz IT, Essien T, Marinda ET, et al. Antiretroviral refusal among newly diagnosed HIV-infected adults in soweto, South Africa. AIDS. 2011;25(17):2177–81.CrossRef
22.
go back to reference Katz IT, Bangsberg DR. Cascade of refusal—what does it mean for the future of treatment as prevention in sub-saharan Africa? Curr HIV/AIDS Rep. 2016;13(2):125–30.CrossRef Katz IT, Bangsberg DR. Cascade of refusal—what does it mean for the future of treatment as prevention in sub-saharan Africa? Curr HIV/AIDS Rep. 2016;13(2):125–30.CrossRef
23.
go back to reference Plazy M, Farouki KE, Iwuji C, et al. Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa. J Int AIDS Soc. 2016;19(1):20913.CrossRef Plazy M, Farouki KE, Iwuji C, et al. Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP cluster-randomized trial in rural South Africa. J Int AIDS Soc. 2016;19(1):20913.CrossRef
24.
go back to reference Sarason IG, Sarason BR, Shearin EN, Pierce GR. A brief measure of social support: practical and theoretical implications. J Soc Pers Relat. 1987;4(4):497–510.CrossRef Sarason IG, Sarason BR, Shearin EN, Pierce GR. A brief measure of social support: practical and theoretical implications. J Soc Pers Relat. 1987;4(4):497–510.CrossRef
25.
go back to reference Wabiri N, Taffa N. Socio-economic inequality and HIV in South Africa. BMC Public Health. 2013;13(1):1037.CrossRef Wabiri N, Taffa N. Socio-economic inequality and HIV in South Africa. BMC Public Health. 2013;13(1):1037.CrossRef
26.
go back to reference Baron EC, Davies T, Lund C. Validation of the 10-item centre for epidemiological studies depression scale (CES-D-10) in Zulu, Xhosa and Afrikaans populations in South Africa. BMC Psychiatry. 2017;17(1):6.CrossRef Baron EC, Davies T, Lund C. Validation of the 10-item centre for epidemiological studies depression scale (CES-D-10) in Zulu, Xhosa and Afrikaans populations in South Africa. BMC Psychiatry. 2017;17(1):6.CrossRef
27.
go back to reference Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med. 1994;10(2):77–84.CrossRef Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D. Am J Prev Med. 1994;10(2):77–84.CrossRef
28.
go back to reference Zhang W, O’Brien N, Forrest JI, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS ONE. 2012;7(7):e40793.CrossRef Zhang W, O’Brien N, Forrest JI, et al. Validating a shortened depression scale (10 item CES-D) among HIV-positive people in British Columbia, Canada. PLoS ONE. 2012;7(7):e40793.CrossRef
29.
go back to reference HSRC. The fifth South African National HIV prevalence incidence behaviour and communication survey 2017: HIV impact assessment summary report. Cape Town: HSRC; 2018. HSRC. The fifth South African National HIV prevalence incidence behaviour and communication survey 2017: HIV impact assessment summary report. Cape Town: HSRC; 2018.
30.
go back to reference Ross J, Sinayobye JD, Yotebieng M, et al. Early outcomes after implementation of treat all in Rwanda: an interrupted time series study. J Int AIDS Soc. 2019;22(4):e25279.CrossRef Ross J, Sinayobye JD, Yotebieng M, et al. Early outcomes after implementation of treat all in Rwanda: an interrupted time series study. J Int AIDS Soc. 2019;22(4):e25279.CrossRef
31.
go back to reference Onoya D, Sineke T, Hendrickson C, et al. Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study. BMJ Open. 2020;10(3):e030228.CrossRef Onoya D, Sineke T, Hendrickson C, et al. Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study. BMJ Open. 2020;10(3):e030228.CrossRef
32.
go back to reference Plazy M, Perriat D, Gumede D, et al. Implementing universal HIV treatment in a high HIV prevalence and rural South African setting–Field experiences and recommendations of health care providers. PLoS ONE. 2017;12(11):e0186883.CrossRef Plazy M, Perriat D, Gumede D, et al. Implementing universal HIV treatment in a high HIV prevalence and rural South African setting–Field experiences and recommendations of health care providers. PLoS ONE. 2017;12(11):e0186883.CrossRef
34.
go back to reference Musheke M, Ntalasha H, Gari S, et al. A systematic review of qualitative findings on factors enabling and deterring uptake of HIV testing in Sub-Saharan Africa. BMC Public Health. 2013;13(1):220.CrossRef Musheke M, Ntalasha H, Gari S, et al. A systematic review of qualitative findings on factors enabling and deterring uptake of HIV testing in Sub-Saharan Africa. BMC Public Health. 2013;13(1):220.CrossRef
35.
go back to reference Vandormael A, de Oliveira T, Tanser F, Bärnighausen T, Herbeck JT. High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study. J Epidemiol Community Health. 2018;72(2):168–72.CrossRef Vandormael A, de Oliveira T, Tanser F, Bärnighausen T, Herbeck JT. High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study. J Epidemiol Community Health. 2018;72(2):168–72.CrossRef
36.
go back to reference Hoddinott G, Myburgh H, de Villiers L, et al. Households, fluidity, and HIV service delivery in Zambia and South Africa – an exploratory analysis of longitudinal qualitative data from the HPTN 071 (PopART) trial. J Int AIDS Soc. 2018;21(S4):e25135.CrossRef Hoddinott G, Myburgh H, de Villiers L, et al. Households, fluidity, and HIV service delivery in Zambia and South Africa – an exploratory analysis of longitudinal qualitative data from the HPTN 071 (PopART) trial. J Int AIDS Soc. 2018;21(S4):e25135.CrossRef
37.
go back to reference Dorward J, Mabuto T, Charalambous S, Fielding KL, Hoffmann CJ. Factors associated with poor linkage to HIV care in South Africa: secondary analysis of data from the Thol’impilo trial. JAIDS. 2017;76(5):453–60.PubMed Dorward J, Mabuto T, Charalambous S, Fielding KL, Hoffmann CJ. Factors associated with poor linkage to HIV care in South Africa: secondary analysis of data from the Thol’impilo trial. JAIDS. 2017;76(5):453–60.PubMed
38.
go back to reference Camlin CS, Akullian A, Neilands TB, et al. Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. Health and Place. 2019;57:339–51.CrossRef Camlin CS, Akullian A, Neilands TB, et al. Gendered dimensions of population mobility associated with HIV across three epidemics in rural Eastern Africa. Health and Place. 2019;57:339–51.CrossRef
39.
go back to reference Tanser F, Bärnighausen T, Vandormael A, Dobra A. HIV treatment cascade in migrants and mobile populations. Curr Opin HIV AIDS. 2015;10(6):430–8.CrossRef Tanser F, Bärnighausen T, Vandormael A, Dobra A. HIV treatment cascade in migrants and mobile populations. Curr Opin HIV AIDS. 2015;10(6):430–8.CrossRef
40.
go back to reference Farel CE, Dennis AM. Why everyone (almost) with HIV needs to be on treatment: a review of the critical data. Infect Dis Clin. 2019;33(3):663–79.CrossRef Farel CE, Dennis AM. Why everyone (almost) with HIV needs to be on treatment: a review of the critical data. Infect Dis Clin. 2019;33(3):663–79.CrossRef
41.
go back to reference Larmarange J, Diallo MH, McGrath N, et al. The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 treatment as prevention trial in rural KwaZulu-Natal (South Africa). J Int AIDS Soc. 2018;21(S4):e25128.CrossRef Larmarange J, Diallo MH, McGrath N, et al. The impact of population dynamics on the population HIV care cascade: results from the ANRS 12249 treatment as prevention trial in rural KwaZulu-Natal (South Africa). J Int AIDS Soc. 2018;21(S4):e25128.CrossRef
Metadata
Title
Understanding the Reasons for Deferring ART Among Patients Diagnosed Under the Same-Day-ART Policy in Johannesburg, South Africa
Authors
Dorina Onoya
Tembeka Sineke
Idah Mokhele
Jacob Bor
Matthew P. Fox
Jacqui Miot
Publication date
01-09-2021
Publisher
Springer US
Published in
AIDS and Behavior / Issue 9/2021
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-021-03171-6

Other articles of this Issue 9/2021

AIDS and Behavior 9/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.